Return of the Switch? A Fallow 2005 Sowed the Seeds for Future Switches
This article was originally published in The Tan Sheet
A Building Yea
You may also be interested in...
Across the board innovation ranging from manufacturing to Rx switch programs is necessary for the OTC industry to spur growth in the future, according to FDA Acting Deputy Commissioner for Operations Janet Woodcock, MD
FDA appears to have issued a "not approvable" letter in response to J&J/Merck's application to switch the cholesterol-lowering drug Mevacor (lovastatin 20 mg) over the counter
The immediate prospects for an OTC statin may have been dampened by the lopsided Mevacor panel vote, but persistent enthusiasm among core decision-makers offers optimism in the long term